Botulinum toxin: New option for refractory lower urinary tract symptoms in women

Clinical Obstetrics and Gynecology

Volumn 51, Issue 1, 2008, Pages 176-186

  Rickey, Leslie M ^a   Kenton, Kimberly ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Botox; Botulinum toxin; Detrusor overactivity; Overactive bladder; Urge incontinence

Indexed keywords

ANTIDOTE; BOTULINUM TOXIN A; BOTULINUM TOXIN A ANTIBODY; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO; TOXIN ANTIBODY; ANTIPARKINSON AGENT; BOTULINUM TOXIN;

ANTIBODY PRODUCTION; BEHAVIOR THERAPY; BLADDER INNERVATION; BOTULISM; BREAST FEEDING; CHRONIC PAIN; CLINICAL TRIAL; CYSTALGIA; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; HISTORY OF MEDICINE; HUMAN; IDIOPATHIC DISEASE; INJECTION SITE REACTION; LOWER URINARY TRACT SYMPTOM; MORBIDITY; MUSCLE WEAKNESS; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; OVERACTIVE BLADDER; PELVIC FLOOR MUSCLE TRAINING; PELVIC ORGAN PROLAPSE; PHYSIOTHERAPY; PREGNANCY; QUALITY OF LIFE; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URETHRA OBSTRUCTION; URGE INCONTINENCE; URINE RETENTION; URODYNAMICS; VISUAL ANALOG SCALE; DRUG RESISTANCE; MUSCLE HYPERTONIA; PATHOLOGY; PELVIS FLOOR; SAFETY;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DRUG RESISTANCE; FEMALE; HUMANS; MUSCLE HYPERTONIA; PELVIC FLOOR; QUALITY OF LIFE; SAFETY; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 41649104936     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/GRF.0b013e3181621fd2     Document Type: Review

References (48)

1. Dasgupta B. Structures of botulinum toxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallet M, eds. Therapy With Botulinum Toxin. New York: Marcel Dekker Inc; 1994.
2. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. J Physiol. 1949;109:10-24.
3. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924-927.
4. Dolly J. General properties and cellular mechanisms of neurotoxins. In: Jankovic J, Hallet M, eds. Therapy With Botulinum Toxin. New York: Marcel Dekker; 1994.
5. Borodic GE, Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol. 1992;12:121-127.
6. Alderson K, Holds JB, Anderson RL. Botulinum-induced alteration of nerve-muscle interactions in the human orbicularis oculi following treatment for blepharospasm. Neurology. 1991;41:1800-1805.
7. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002;96:105-113.
8. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49:701-707.
9. Eleopra R, Tugnoli V, Rossetto O, et al. Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human. Neurosci Lett. 1997;224:91-94.
10. Mezaki T, Kaji R, Kohara N, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology. 1995;4 5(3 Pt 1):506-508.
11. Brin MF, Blitzer A. Botulinum toxin: dangerous terminology errors. J R Soc Med. 1993;86:493-494.
12. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40:599-600.
13. Giannantoni A, Di Stasi SM, Stephen RL, et al. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol. 2004;172:240-243.
14. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord. 1988;3:333-335.
15. Scott AB. Clostridial toxins as therapeutic agents. In: Simpson L, ed. Botulinum Toxin and Tetanus Toxin. New York: Academic Press; 1989.
16. Moser E, Ligon K, Singer C. Botulinum toxinA(Botox) therapy during pregnancy [Abstract]. Neurology. 1997;48:399.
17. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta B, ed. Botulinum and Tetanus Neurotoxions: Neurotransmission and Biomedical Aspects. New York: Plenum Press; 1993.
18. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213-217.
19. Kessler KR, Benecke R. The EBD test - a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord. 1997;12:95-99.
20. Pistolesi D, Selli C, Rossi B, et al. Botulinum toxin type B for type A resistant bladder spasticity.JUrol. 2004;171(2 Pt 1):802-803.
21. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol. 2004;171(2 Pt 1):804; discussion 804-805.
22. Harper M, Popat RB, Dasgupta R, et al. A minimally invasive technique for out-patient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int. 2003;92:325-326.
23. Cohen BL, Rivera R, Barboglio P, et al. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol. 2007;177:1006-1010; discussion 1010.
24. Karsenty G, Elzayat E, Delapparent T, et al. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol. 2007;177:1011-1014.
25. Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178(4 Pt 1):1359-1363.
26. Kuo HC. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions. Urology. 2006;67:232-236.
27. Schurch B, Stohrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3 Pt 1):692-697.
28. Karsenty G, Boy S, Reitz A. Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI) - a prospective randomized trial to compare 30 versus 10 injection sites. Presented at 35th Annual Meeting of the International Continence Society, 2005, Montral, Canada.
29. Reitz A, Stohrer M, Kramer G, et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol. 2004;45:510-515.
30. Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196-200.
31. Denys P, Schurch B, De Seze M, et al. Significant improvements in incontinence quality of life instrument scores following botulinum toxin A treatment of patients with neurogenic urinary incontinence. Presented at European Association of Urology Annual Congress; 2005; Istanbul, Turkey.
32. Kalsi V, Apostolidis A, Popat R, et al. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol. 2006;49:528-535.
33. Patki PS, Hamid R, Arumugam K, et al. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int. 2006;98:77-82.
34. Flynn MK, Webster GD, Amundsen CL. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol. 2004;172(6 Pt 1):2316-2320.
35. Kessler TM, Danuser H, Schumacher M, et al. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn. 2005;24:231-236.
36. Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology. 2006;68:993-997;discussion 997-998.
37. Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol. 2005;48:984-990; discussion 990.
38. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol. 2006;176:177-185.
39. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231-2236.
40. Cottrell A, Stott M. Two years experience of intra-detrusor botulinum A toxin for idiopathic detrusor overactivity: Duration of action, quality of life, and frequency/volume measurements. Presented at 36th Annual Meeting of the International Continence Society; 2006; Christchurch, New Zealand.
41. Ghalayini IF, Al-Ghazo MA. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction. Neurourol Urodyn. 2007;26:531-536.
42. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24-26.
43. Schurch B, Hauri D, Rodic B, et al. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol. 1996;155:1023-1029.
44. Petit H, Wiart L, Gaujard E, et al. Botulinum A toxin treatment for detrusorsphincter dyssynergia in spinal cord disease. Spinal Cord. 1998;36:91-94.
45. Smith CP, O'Leary M, Erickson J, et al. Botulinum toxin urethral sphincter injection resolves urinary retention after pubovaginal sling operation. Int Urogynecol J Pelvic Floor Dysfunct. 2002;13:185-186.
46. Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine. Dis Mon. 2002;48:323-335.
47. Giannantoni A, Costantini E, Di Stasi SM, et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49:704-709.
48. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol. 2004;104(5 Pt 1):922-925.